Thrivent Financial for Lutherans
LCTX icon

Thrivent Financial for Lutherans’s Lineage Cell Therapeutics LCTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Hold
10,000
– – ﹤0.01% 2588
2026
Q1 		$16K Hold
10,000
– – ﹤0.01% 2520
2025
Q4 		$17K Buy
+10,000
New +$17.3K ﹤0.01% 2560
2025
Q3 		– Sell
-10,000
Closed -$9K – 2520
2025
Q2 		$9K Buy
+10,000
New +$5.93K ﹤0.01% 2424
2025
Q1 		– Sell
-10,000
Closed -$5K – 2473
2024
Q4 		$5K Buy
+10,000
New +$7.34K ﹤0.01% 2547
2024
Q2 		– Sell
-15,000
Closed -$22K – 2557
2024
Q1 		$22K Hold
15,000
– – ﹤0.01% 2501
2023
Q4 		$16K Hold
15,000
– – ﹤0.01% 2475
2023
Q3 		$18K Hold
15,000
– – ﹤0.01% 2423
2023
Q2 		$21K Hold
15,000
– – ﹤0.01% 2450
2023
Q1 		$22K Hold
15,000
– – ﹤0.01% 2429
2022
Q4 		$18K Hold
15,000
– – ﹤0.01% 2402
2022
Q3 		$17K Buy
+15,000
New +$22K ﹤0.01% 2398
2021
Q4 		– Sell
-42,533
Closed -$107K – 2485
2021
Q3 		$107K Sell
42,533
-137
-0.3% -$351 ﹤0.01% 2449
2021
Q2 		$121K Buy
+42,670
New +$110K ﹤0.01% 2432

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Thrivent Financial for Lutherans's LCTX Position: Q2 2026 in Review

Thrivent Financial for Lutherans held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 10,000 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #2588.

Thrivent Financial for Lutherans first reported a position in LCTX in Q2 2021 and has held it in 14 quarters since. The position peaked at $121K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Thrivent Financial for Lutherans held 10,000 shares of Lineage Cell Therapeutics worth $13K as of Q2 2026.
  • Thrivent Financial for Lutherans left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2588 holding.
  • Thrivent Financial for Lutherans first reported a position in Lineage Cell Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • Thrivent Financial for Lutherans's Lineage Cell Therapeutics position peaked at $121K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.